疏肝益肾方联合内分泌药物对人乳腺癌MCF-7、MDA-MB-231细胞增殖、凋亡的影响  

Effect of Shugan Yishen Prescription Combined with Endocrine Drug on Proliferation and Apoptosis of Breast Cancer MCF-7,MDA-MB-231 Cells

作　　者：郝满霞[1] 王希瑞[1] 李伟汉 HAO Manxia;WANG Xirui;LI Weihan(The First People＇s Hospital of Nanyang City)

机构地区：[1]南阳市第一人民医院,河南南阳473000

出　　处：《中医学报》2018年第3期367-370,共4页Acta Chinese Medicine

基　　金：河南省杰出人才创新基金资助项目(0623136921);河南省创新型科技人才队伍建设工程基金项目(2014GG032)

摘　　要：目的:探讨疏肝益肾方联合内分泌药物对激素依赖型乳腺癌患者人乳腺癌MCF-7、MDA-MB-231细胞增殖凋亡的影响。方法:选择确诊为激素依赖型乳腺癌患者作为研究对象,采用随机数字表法将其分为观察组和对照组。观察组给予疏肝益肾方联合内分泌药物治疗,对照组给予内分泌药物治疗。观察两组患者临床治疗效果及人乳腺癌MCF-7、MDA-MB-231的表达。结果:治疗后两组患者CA125、CA153水平较治疗前有明显升高(P<0.05),且观察组明显优于对照组(P<0.05);治疗后,对照组CD_3^+、CD_4^+、CD_4^+/CD_8^+下降,CD^(8+)上升,观察组CD_3^+、CD_4^+、CD_4^+/CD_8^+升高,CD^(8+)下降,两组比较,差异有统计学意义(P<0.05);两组患者治疗后MCF-7、MDA-MB-231细胞增殖抑制作用有显著提高(P<0.05),且观察组显著优于对照组(P<0.05);两组患者治疗后细胞凋亡率明显上升(P<0.05),且观察组显著优于对照组(P<0.05);治疗后观察组1年生存率、2年生存率、中位疾病进展时间及转移后中位生存期均明显高于对照组(P<0.05)。结论:疏肝益肾方联合内分泌药物治疗激素依赖型乳腺癌疗效显著,能够抑制MCF-7、MDA-MB-231细胞的增殖和加快其凋亡。Objective： To investigate the effect of Shugan Yishen prescription combined with endocrine drug on proliferation and apoptosis of Breast cancer MCF-7,MDA-MB-231 cells. Methods： From June 2014 to June 2016,172 cases of Hormone dependent breast cancer patients were be chosen as the research object and were randomly divided into observation group and control group.The observation group was treated with Shugan Yishen prescription Combined with endocrine drug,while the control group was given endocrine treatment. The clinical efficacy of two groups and the expression of MCF-7 and MDA-MB-231 in breast cancer cells were observed. Results： After treatment,CA125 and CA153 levels significantly increased than that before treatment（P〈0. 05）,and that of the observation group was significantly lower than that of the control group（P〈0. 05）. After treatment,CD3^＋,CD4^＋,CD4^＋/CD8^＋of the control group decreased and CD^8＋increased,while CD3^＋,CD4^＋,CD4^＋/CD8^＋the observation group increased and CD^8＋decreased,with the differences being statistically significant（P〈0. 05）. After treatment,MCF-7 and MDA-MB-231 cell proliferation was significantly increased,and that of the observation group was significantly higher than that of the control group（P〈0. 05）. After treatment,cell apoptosis rates increased significantly,and that of the observation group was higher than that of the control group（P〈0. 05）. One years and 2 years after treatment,the survival rate,survival rate,TTP and MSR of the observation group were significantly higher than that of the control group（P〈0. 05）. Conclusion： Shugan Yishen prescription combined with endocrine drug has significant effect on hormone dependent breast cancer. It can inhibit the proliferation of MCF-7 and MDAMB-231 cells and accelerate their apoptosis.

关 键 词：激素依赖型乳腺癌 疏肝益肾方 内分泌药物 MCF-7细胞 MDA-MB-231细胞 肿瘤 

分 类 号：R273.379[医药卫生—中西医结合]